Literature DB >> 8945598

Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin.

L de Haan1, W R Verweij, I K Feil, T H Lijnema, W G Hol, E Agsteribbe, J Wilschut.   

Abstract

The Escherichia coli heat-labile enterotoxin (LT) is a potent inducer of mucosal immune responses. In a previous study (L. DeHaan, W. R. Verweij, M. Holtrop, E. Agsteribbe, and J. Wilschut, Vaccine 14:620-626, 1996), we have shown that efficient induction of an LTB-specific mucosal immune response by LT requires the presence of the LTA chain, suggesting a possible role of the enzymatic activity of LTA in the induction of these responses. In the present study, we generated LT mutants with altered ADP-ribosylation activities and evaluated their immunogenicity upon intranasal administration to mice. The results demonstrate that the mucosal immunogenicity of LT is not dependent on its ADP-ribosylation activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8945598      PMCID: PMC174540          DOI: 10.1128/iai.64.12.5413-5416.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

Review 1.  The mucosal immune system: from fundamental concepts to vaccine development.

Authors:  J R McGhee; J Mestecky; M T Dertzbaugh; J H Eldridge; M Hirasawa; H Kiyono
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

2.  Whole cholera toxin and B subunit act synergistically as an adjuvant for the mucosal immune response of mice to keyhole limpet haemocyanin.

Authors:  A D Wilson; C J Clarke; C R Stokes
Journal:  Scand J Immunol       Date:  1990-04       Impact factor: 3.487

3.  Reduction in oral immunogenicity of cholera toxin B subunit by N-terminal peptide addition.

Authors:  M T Dertzbaugh; C O Elson
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

Review 4.  Live oral vaccines against cholera: an update.

Authors:  M M Levine; J B Kaper
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

5.  Mapping epitopic regions of cholera toxin B-subunit protein.

Authors:  M Kazemi; R A Finkelstein
Journal:  Mol Immunol       Date:  1991-08       Impact factor: 4.407

6.  Mutant alpha subunits of Gi2 inhibit cyclic AMP accumulation.

Authors:  Y H Wong; A Federman; A M Pace; I Zachary; T Evans; J Pouysségur; H R Bourne
Journal:  Nature       Date:  1991-05-02       Impact factor: 49.962

7.  Cytoplasmic high-level expression of a soluble, enzymatically active form of the Escherichia coli penicillin-binding protein 5 and purification by dye chromatography.

Authors:  M P van der Linden; H Mottl; W Keck
Journal:  Eur J Biochem       Date:  1992-02-15

8.  Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up.

Authors:  J D Clemens; D A Sack; J R Harris; F Van Loon; J Chakraborty; F Ahmed; M R Rao; M R Khan; M Yunus; N Huda
Journal:  Lancet       Date:  1990-02-03       Impact factor: 79.321

Review 9.  Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin.

Authors:  B D Spangler
Journal:  Microbiol Rev       Date:  1992-12

10.  The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity.

Authors:  N Lycke; T Tsuji; J Holmgren
Journal:  Eur J Immunol       Date:  1992-09       Impact factor: 5.532

View more
  17 in total

Review 1.  M cell-targeted mucosal vaccine strategies.

Authors:  M Yamamoto; D W Pascual; H Kiyono
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

2.  Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin.

Authors:  G Douce; M Fontana; M Pizza; R Rappuoli; G Dougan
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

3.  Differential regulation of macrophage interleukin-1 (IL-1), IL-12, and CD80-CD86 by two bacterial toxins.

Authors:  D L Foss; M J Zilliox; M P Murtaugh
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

4.  A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking.

Authors:  Yukari Hagiwara; Yuki I Kawamura; Kosuke Kataoka; Bibi Rahima; Raymond J Jackson; Katsuhiro Komase; Taeko Dohi; Prosper N Boyaka; Yoshifumi Takeda; Hiroshi Kiyono; Jerry R McGhee; Kohtaro Fujihashi
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

5.  Nasal vaccination with the 40-kilodalton outer membrane protein of Porphyromonas gingivalis and a nontoxic chimeric enterotoxin adjuvant induces long-term protective immunity with reduced levels of immunoglobulin E antibodies.

Authors:  Fumiki Momoi; Tomomi Hashizume; Tomoko Kurita-Ochiai; Yoshikazu Yuki; Hiroshi Kiyono; Masafumi Yamamoto
Journal:  Infect Immun       Date:  2008-04-14       Impact factor: 3.441

6.  Identification of an iron-sulfur cluster that modulates the enzymatic activity in NarE, a Neisseria meningitidis ADP-ribosyltransferase.

Authors:  Mariangela Del Vecchio; Rebecca Pogni; Maria Camilla Baratto; Angela Nobbs; Rino Rappuoli; Mariagrazia Pizza; Enrico Balducci
Journal:  J Biol Chem       Date:  2009-09-10       Impact factor: 5.157

Review 7.  Dendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccines.

Authors:  Kosuke Kataoka; Kohtaro Fujihashi
Journal:  Expert Rev Vaccines       Date:  2009-09       Impact factor: 5.217

8.  Mucosal immunogenicity and adjuvant activity of the recombinant A subunit of the Escherichia coli heat-labile enterotoxin.

Authors:  L De Haan; M Holtrop; W R Verweij; E Agsteribbe; J Wilschut
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

9.  Secretory expression and purification of recombinant Escherichia coli heat-labile enterotoxin B subunit and its applications on intranasal vaccination of hantavirus.

Authors:  Shouchun Cao; Ying Zhang; Feng Liu; Qin Wang; Quanfu Zhang; Qinzhi Liu; Chuan Li; Mifang Liang; Dexin Li
Journal:  Mol Biotechnol       Date:  2008-12-17       Impact factor: 2.695

10.  Mutant Escherichia coli heat-labile toxin B subunit that separates toxoid-mediated signaling and immunomodulatory action from trafficking and delivery functions.

Authors:  Sylvia A Fraser; Lolke de Haan; Arron R Hearn; Heather K Bone; Robert J Salmond; A Jennifer Rivett; Neil A Williams; Timothy R Hirst
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.